Prostate cryoablation: A mini review

Xia Zheng; Lihui Chen; Kaiting Lai; Zhiyong Li

doi:10.2478/fzm-2023-0032

Prostate cryoablation: A mini review

doi: 10.2478/fzm-2023-0032

Xia Zheng^{1, 2, #},
Lihui Chen^{1, 3, #},
Kaiting Lai^{1, 2, #},
Zhiyong Li^{1, 2
, ,}

1.
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China
2.
Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
3.
Department of Head and NeckSurgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, China

Funds:

the National Natural Science Foundation of China 82203320

More Information

Corresponding author: Zhiyong Li, E-mail: lizhiy@sysucc.org.cn

摘要

Abstract: In recent years, cryotherapy has gained increasing acceptance as a treatment for prostate cancer, offering complementary therapeutic benefits when combined with radical surgery and radiotherapy. Despite the potential for surgical complications, it stands as a safe and viable therapeutic modality. Cryotherapy provides an efficient approach for elderly patients, especially those with compromised physical conditions and individuals experiencing recurrence after initial treatment. It has shown promise in extending survival periods and improving the overall quality of life for these patients. This article aims to comprehensively examine the developmental trajectory, surgical techniques, indications, therapeutic outcomes, and potential complications associated within prostate cancer treatment.
- prostate cancer /
- prostate cryoablation

HTML全文

Table 1. Therapeutic efficacy and complications of cryotherapy for prostate cancer

Reference	n	Therapeutic efficacy	Complications
Ward et al.^[14]	1160	3-year biochemical recurrence (BCR)-free survival 75.7%	urinary incontinence 1.6% impotence 41.9%
Li et al.^[15]	91	1, 3, 5-year BCR-free survival: 95.3%, 72.4%, and 46.5%	urinary incontinence 5.5% impotence 50%
Valerio et al.^[16]	3230	overall survival: 100%	urinary incontinence: 0 impotence: 19.5%

下载: 导出CSV

参考文献(20)

[1]	Feng R M, Zong Y N, Cao S M, et al. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? Cancer Commun (Lond), 2019; 39(1): 22.
[2]	Zhou Z G, Qin J, Song C L, et al. circROBO1 promotes prostate cancer growth and enzalutamide resistance via accelerating glycolysis. J Cancer, 2023; 14(13): 2574–2584. doi: 10.7150/jca.86940
[3]	Liu X, Yu C, Bi Y, et al. Trends and age-period-cohort effect on incidence and mortality of prostate cancer from 1990 to 2017 in China. Public Health, 2019; 172: 70–80. doi: 10.1016/j.puhe.2019.04.016
[4]	Kongnyuy M, Halpern D M, Kosinski K E, et al. Cryosurgery, an alternative treatment option for organ-confined prostate cancer: Current beliefs and practice patterns of urologists. Int Urol Nephrol, 2017; 49(1): 43–48. doi: 10.1007/s11255-016-1440-7
[5]	Onik G M, Cohen J K, Reyes G D, et al. Transrectal ultrasound guided percutaneous radical cryosurgical ablation of the prostate. Cancer, 1993; 72(4): 1291–1299. doi: 10.1002/1097-0142(19930815)72:4<1291::AID-CNCR2820720423>3.0.CO;2-I
[6]	Song K D. Percutaneous cryoablation for hepatocellular carcinoma. Clin Mol Hepatol, 2016; 22(4): 509–515. doi: 10.3350/cmh.2016.0079
[7]	Langenhuijsen J F, Broers E M, Vergunse H. Cryosurgery for prostate cancer: an update on clinical results of modern cryotechnology. Eur Urol, 2009; 55(1): 76–86. doi: 10.1016/j.eururo.2008.08.063
[8]	Chosy S G, Nakada S Y, Lee F T, et al. Monitoring renal cryosurgery: predictors of tissue necrosis in swine. J Urol, 1998; 159(4): 1370–1374. doi: 10.1016/S0022-5347(01)63618-8
[9]	Ravindranath M H, Wood T F, Soh D, et al. Cryosurgical ablation of liver tumors in colon cancer patients increases the serum total ganglioside level and then selectively augments anti-ganglioside IgM. Cryobiology, 2002; 45(1): 10–21. doi: 10.1016/S0011-2240(02)00102-5
[10]	Sanda M G, Cadeddu J A, Kirk B Y E, et al. Clinically Localized Prostate Cancer: A UA/ASTRO/SUO Guideline. Part Ⅰ: Risk stratification, shared decision making, and care options. J Urol, 2018; 199(3): 683–690. doi: 10.1016/j.juro.2017.11.095
[11]	Mohler J L, Lee R J, Antonarakis E S, et al. Prostate Cancer, version 2, 2018. NCCN clinical practice guidelines.
[12]	Lian H, Yan G R, Li N T, et al. Salvage cryotherapy with third generation technology for locally recurrent prostate cancer after radiation therapy. Int Urol Nephrol, 2016; 48(9): 1461–1466. doi: 10.1007/s11255-016-1339-3
[13]	Edison E, Tariq Shah T, Ahmed H U. Focal Ablation of Early Stage Prostate Cancer Candidate Selection, Treatment Guidance, and Assessment of Outcome. Urol Clin North Am, 2017; 44(4): 575–585. doi: 10.1016/j.ucl.2017.07.006
[14]	Ward J F, Jones J S. Focal cryotherapy for localized pros tate cancer: a report from the national Cryo On-Line Database (COLD) Registry. BJU Int, 2012; 109(11): 648–1654.
[15]	Li Y H, Elshafei A, Agarwal G, et al. Salvage focal prostate cryoablation for locally recurrent prostate cancer after radiotherapy: initial results from the cryo on-line data registry. Prostate, 2015; 75(1): 1–7. doi: 10.1002/pros.22881
[16]	Valerio M, Cerantola Y, Eggener S E, et al. New and established technology in focal ablation of the prostate: a systematic review. EurUrol, 2017; 71(1): 17–34.
[17]	Chen C H, Tsai C Y, Pu Y S. Primary Total Prostate Cryoablation for Localized High-Risk Prostate Cancer: 10-Year Outcomes and Nomograms. Cancers (Basel). 2023; 15(15): 3873. doi: 10.3390/cancers15153873
[18]	Bahn D, de Castro Abreu A L, Gill I S, et al. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol, 2012; 62: 55–63. doi: 10.1016/j.eururo.2012.03.006
[19]	Donnelly B J, Saliken J C, Brasher P M, et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer, 2010; 116: 323–330. doi: 10.1002/cncr.24779
[20]	Jones J S, Rewcastle J C, Donnelly B J, et al. Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry. J Urol, 2008; 180(2): 554–558. doi: 10.1016/j.juro.2008.04.027